Ignacio Vazquez-Garcia
@ignaciovazquez.bsky.social
Assistant Professor @ Massachusetts General Hospital | Harvard Medical School | Broad Institute
https://vazquezgarcialab.mgh.harvard.edu/
https://vazquezgarcialab.mgh.harvard.edu/
We are assembling an exceptional multidisciplinary team, and we are currently hiring! Let's connect: vazquezgarcialab.mgh.harvard.edu [13/13]
Vazquez-Garcia Lab
Vazquez-Garcia Lab @ [Massachusetts General Hospital](https://www.massgeneral.org/) | [Harvard Medical School](https://hms.harvard.edu/) | [Broad Institute of MIT and Harvard](https://www.broadinstitu...
vazquezgarcialab.mgh.harvard.edu
September 3, 2025 at 1:58 PM
We are assembling an exceptional multidisciplinary team, and we are currently hiring! Let's connect: vazquezgarcialab.mgh.harvard.edu [13/13]
If you are excited by this kind of work, I am building my new lab at Massachusetts General Hospital, Harvard Medical School, and the Broad Institute. 🧬🔬 @mgbresearch.bsky.social @harvardmed.bsky.social @broadinstitute.org #NewPI #AcademicTwitter [12/13]
September 3, 2025 at 1:58 PM
If you are excited by this kind of work, I am building my new lab at Massachusetts General Hospital, Harvard Medical School, and the Broad Institute. 🧬🔬 @mgbresearch.bsky.social @harvardmed.bsky.social @broadinstitute.org #NewPI #AcademicTwitter [12/13]
Thank you also to the entire MSK SPECTRUM team @mskcancercenter.bsky.social. Deeply grateful to @cycleforsurvival.bsky.social, OCRA, CDMRP and @cancergrand.bsky.social for their generous support. [11/13]
September 3, 2025 at 1:58 PM
Thank you also to the entire MSK SPECTRUM team @mskcancercenter.bsky.social. Deeply grateful to @cycleforsurvival.bsky.social, OCRA, CDMRP and @cancergrand.bsky.social for their generous support. [11/13]
This study reflects the collective efforts of an extraordinary team. I am especially thankful to @sohrabshah.bsky.social for his guidance and mentorship, and to Andrew McPherson, Matt Myers, Duaa Al-Rawi, and Matthew Zatzman for an outstanding collaboration. [10/13]
September 3, 2025 at 1:58 PM
This study reflects the collective efforts of an extraordinary team. I am especially thankful to @sohrabshah.bsky.social for his guidance and mentorship, and to Andrew McPherson, Matt Myers, Duaa Al-Rawi, and Matthew Zatzman for an outstanding collaboration. [10/13]
For a broader perspective on the therapeutic relevance of our findings, please check out the @nature.com News & Views by Nikki Burdett and Elizabeth Christie, which discusses WGD as a potential clinical target:
www.nature.com/articles/d41... [9/13]
www.nature.com/articles/d41... [9/13]
Genome doubling fuels ovarian cancer evolution and immune dysregulation
Single-cell analysis reveals the extent of genome doubling in ovarian cancer, its variability and its role in enabling tumours to evade the immune system.
www.nature.com
September 3, 2025 at 1:58 PM
For a broader perspective on the therapeutic relevance of our findings, please check out the @nature.com News & Views by Nikki Burdett and Elizabeth Christie, which discusses WGD as a potential clinical target:
www.nature.com/articles/d41... [9/13]
www.nature.com/articles/d41... [9/13]
For a succinct summary of our work, please see Safia Danovi’s research highlight in @natgenet.nature.com, capturing the key findings and implications of WGD dynamics in HGSOC:
www.nature.com/articles/s41... [8/13]
www.nature.com/articles/s41... [8/13]
Whole-genome doubling in ovarian cancer - Nature Genetics
Nature Genetics - Whole-genome doubling in ovarian cancer
www.nature.com
September 3, 2025 at 1:58 PM
For a succinct summary of our work, please see Safia Danovi’s research highlight in @natgenet.nature.com, capturing the key findings and implications of WGD dynamics in HGSOC:
www.nature.com/articles/s41... [8/13]
www.nature.com/articles/s41... [8/13]
So what is the big picture? Our work redefines WGD as a dynamic mutational process that promotes genomic diversification and immune escape. WGD status may serve as a new biomarker to guide therapies like PARP inhibitors and inform the development of future targeted agents. [7/13]
September 3, 2025 at 1:58 PM
So what is the big picture? Our work redefines WGD as a dynamic mutational process that promotes genomic diversification and immune escape. WGD status may serve as a new biomarker to guide therapies like PARP inhibitors and inform the development of future targeted agents. [7/13]
How do WGD tumors tolerate instability and evade immune sensing? WGD alters cell state: it delays G1/S, represses STING and IFN signaling, and decouples immune activation from chromosomal chaos despite abundant cytosolic DNA from ruptured micronuclei. [6/13]
September 3, 2025 at 1:58 PM
How do WGD tumors tolerate instability and evade immune sensing? WGD alters cell state: it delays G1/S, represses STING and IFN signaling, and decouples immune activation from chromosomal chaos despite abundant cytosolic DNA from ruptured micronuclei. [6/13]
Despite elevated chromosomal instability, WGD-high tumors exhibit tolerance to progressive karyotypic disruption, favoring gradual, post-WGD copy number losses. This supports a model where WGD promotes diversification via genomic remodeling. [5/13]
September 3, 2025 at 1:58 PM
Despite elevated chromosomal instability, WGD-high tumors exhibit tolerance to progressive karyotypic disruption, favoring gradual, post-WGD copy number losses. This supports a model where WGD promotes diversification via genomic remodeling. [5/13]
WGD was linked to elevated chromosomal instability: copy number alterations, missegregations, and ruptured micronuclei. We quantified these rates at single-cell resolution, using scWGS + phylogenetic analysis and multiplexed IF + deep learning-based image segmentation. [4/13]
September 3, 2025 at 1:58 PM
WGD was linked to elevated chromosomal instability: copy number alterations, missegregations, and ruptured micronuclei. We quantified these rates at single-cell resolution, using scWGS + phylogenetic analysis and multiplexed IF + deep learning-based image segmentation. [4/13]
We found that WGD is not a static or historical event. Nearly all tumors exhibited mixtures of 0×, 1×, and 2× WGD cells. Several tumors showed parallel WGD events in distinct subclones, while others displayed the emergence of new WGD clones late in evolution. [3/13]
September 3, 2025 at 1:58 PM
We found that WGD is not a static or historical event. Nearly all tumors exhibited mixtures of 0×, 1×, and 2× WGD cells. Several tumors showed parallel WGD events in distinct subclones, while others displayed the emergence of new WGD clones late in evolution. [3/13]
To answer this, we generated single-cell whole-genome sequencing (scWGS) data from >30,000 tumor cells across 41 patients with high-grade serous ovarian cancer (HGSOC). We integrated this with multiplexed immunofluorescence (IF) and single-cell RNA-seq data. [2/13]
September 3, 2025 at 1:58 PM
To answer this, we generated single-cell whole-genome sequencing (scWGS) data from >30,000 tumor cells across 41 patients with high-grade serous ovarian cancer (HGSOC). We integrated this with multiplexed immunofluorescence (IF) and single-cell RNA-seq data. [2/13]
Thread 🪡:
WGD is common in human cancer and has been linked to poor prognosis, drug resistance, and metastatic dissemination. But when does WGD occur? Is it a one-time event or an ongoing process during tumor evolution? And what are its phenotypic consequences? [1/13]
WGD is common in human cancer and has been linked to poor prognosis, drug resistance, and metastatic dissemination. But when does WGD occur? Is it a one-time event or an ongoing process during tumor evolution? And what are its phenotypic consequences? [1/13]
September 3, 2025 at 1:58 PM
Thread 🪡:
WGD is common in human cancer and has been linked to poor prognosis, drug resistance, and metastatic dissemination. But when does WGD occur? Is it a one-time event or an ongoing process during tumor evolution? And what are its phenotypic consequences? [1/13]
WGD is common in human cancer and has been linked to poor prognosis, drug resistance, and metastatic dissemination. But when does WGD occur? Is it a one-time event or an ongoing process during tumor evolution? And what are its phenotypic consequences? [1/13]
Thank you!
January 11, 2025 at 6:10 PM
Thank you!
Thank you!
January 11, 2025 at 6:10 PM
Thank you!
We are seeking exceptionally curious and driven scientists at all stages (postdocs, grad students, undergraduates, research associates) – both computational and experimental! Please reach out if you have an interest in joining, collaborating, or have advice for a new PI! (7/7)
January 7, 2025 at 5:18 AM
We are seeking exceptionally curious and driven scientists at all stages (postdocs, grad students, undergraduates, research associates) – both computational and experimental! Please reach out if you have an interest in joining, collaborating, or have advice for a new PI! (7/7)
I excitedly look forward to joining the world-class science and outstanding community at MGH Pathology, MGH Cancer Center and Broad, who have already made me feel most welcome on my first day. (6/7)
January 7, 2025 at 5:18 AM
I excitedly look forward to joining the world-class science and outstanding community at MGH Pathology, MGH Cancer Center and Broad, who have already made me feel most welcome on my first day. (6/7)
My deepest gratitude goes to my exceptional mentors, colleagues, collaborators, sponsors, family and friends. 🙏 @mskcancercenter.bsky.social @mskeducation.bsky.social @columbiauniversity.bsky.social @sangerinstitute.bsky.social @cancergrand.bsky.social @wellcometrust.bsky.social (5/7)
January 7, 2025 at 5:18 AM
My deepest gratitude goes to my exceptional mentors, colleagues, collaborators, sponsors, family and friends. 🙏 @mskcancercenter.bsky.social @mskeducation.bsky.social @columbiauniversity.bsky.social @sangerinstitute.bsky.social @cancergrand.bsky.social @wellcometrust.bsky.social (5/7)
Our ultimate goal is to impact human health and clinical care for patients, leveraging our understanding of cancer trajectories to enable biomarkers and therapeutic strategies that anticipate and overcome tumor progression. (4/7)
January 7, 2025 at 5:18 AM
Our ultimate goal is to impact human health and clinical care for patients, leveraging our understanding of cancer trajectories to enable biomarkers and therapeutic strategies that anticipate and overcome tumor progression. (4/7)
We will focus on quantitative approaches to study cellular dynamics in tumors, combining new high-throughput genomics and AI/ML approaches with large clinical datasets and experimental models. (3/7)
January 7, 2025 at 5:18 AM
We will focus on quantitative approaches to study cellular dynamics in tumors, combining new high-throughput genomics and AI/ML approaches with large clinical datasets and experimental models. (3/7)